Betatrophin与非酒精性脂肪性肝病

doi:10.3969/j.issn.1672-5069.2023.06.041

Abstract

Abstract: Objective Nonalcoholic fatty liver diseases (NAFLD) is a kind of liver injury caused by metabolic stress. With the prevalence of obesity and metabolic syndrome (MetS), the NAFLD has become the most popular chronic liver disease in China. Betatrophin is a newly discovered glycoprotein closely related to glucose and lipid metabolism and insulin resistance (IR), which may be closely related to the onset and progression of NAFLD. This article reviewed the role of betatrophin in the process and development of NAFLD.

Key words: Nonalcoholic fatty liver diseases, Betatrophin, Glucose and Lipid metabolism, Insulin resistance

Han Shishan, Zhao Caiyan. Perspective of betatrophin in the development of nonalcoholic fatty liver diseases[J]. Journal of Practical Hepatology, 2023, 26(6): 930-933.

References

[1] Diehl AM,Day C. Cause, pathogenesis, and treatment of nonalcoholic steatohepatitis. N Engl J Med, 2017, 377(21): 2063-2072.
[2] 中华医学会肝病学分会脂肪肝和酒精性肝病学组,中国医师协会脂肪性肝病专家委员会. 非酒精性脂肪性肝病防治指南(2018年更新版) .实用肝脏病杂志. 2018, 21(02): 177-186.
[3] Ren G, Kim JY, Smas CM. Identification of RIFL, a novel adipocyte-enriched insulin target gene with a role in lipid metabolism. Am J Physiol Endocrinol Metab, 2012, 303(3): 334-351.
[4] Zhang R. Lipasin, a novel nutritionally-regulated liver-enriched factor that regulates serum triglyceride levels. Biochem Biophys Res Commun, 2012, 424(4): 786-792.
[5] Quagliarini F, Wang Y, Kozlitina J, et al. Atypical angiopoietin-like protein that regulates ANGPTL3. Proc Natl Acad Sci U S A, 2012, 109(48): 19751-19756.
[6] Yi P, Park JS, Melton DA. Betatrophin: a hormone that controls pancreatic β cell proliferation. Cell, 2013, 153(4): 747-758.
[7] Fu Z, Yao F, Abou-Samra AB, et al. Lipasin, thermoregulated in brown fat, is a novel but atypical member of the angiopoietin-like protein family. Biochem Biophys Res Commun, 2013, 430(3): 1126-1131.
[8] Tseng YH, Ke PY, Liao CJ, et al. Chromosome 19 open reading frame 80 is upregulated by thyroid hormone and modulates autophagy and lipid metabolism. Autophagy, 2014, 10(1): 20-31.
[9] Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology, 2016, 64(1): 73-84.
[10] Fan JG, Kim SU, Wong VW. New trends on obesity and NAFLD in Asia. J Hepatol, 2017, 67(4): 862-873.
[11] Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism, 2016, 65(8): 1038-1048.
[12] Benedict M, Zhang X. Non-alcoholic fatty liver disease: An expanded review. World J Hepatol, 2017, 9(16): 715-732.
[13] Von Loeffelholz C, Pfeiffer AFH, Lock JF, et al. ANGPTL8 (Betatrophin) isexpressed in visceral adipose tissue and relates to human hepatic steatosis in two independent clinical collectives. Horm Metab Res, 2017, 49(5): 343-349.
[14] Hong BS, Liu J, Zheng J, et al. Angiopoietin-like protein 8/betatrophin correlates with hepatocellular lipid content independent of insulin resistance in non-alcoholic fatty liver disease patients. J Diabetes Investig, 2018, 9(4): 952-958.
[15] Hu W, Shao X, Guo D, et al. Relationship ofserum betatrophin with nonalcoholic fatty liver in a Chinese population. PLoS One, 2017, 12(1): 1-10.
[16] 张长军. 非酒精性脂肪性肝病患者血清ALT、AST、betatrophin水平变化与意义.现代医学与健康研究电子杂志. 2021, 5(1): 101-102.
[17] 龙柳艳,韦晓谋. 非酒精性脂肪性肝病患者血清Betatrophin 水平评估病情严重程度的应用价值.肝脏, 2019, 24(8): 933-935.
[18] 邵小娟, 金海涛, 胡文, 等. 血清Betatrophin预测非酒精性脂肪肝及其进展的作用 .中华临床医师杂志(电子版). 2017, 11(3): 404-408.
[19] Cengiz M, Ozenirler S, Kocabiyik M. Serum β-trophin level as a new marker for noninvasive assessment of nonalcoholic fatty liver disease and liver fibrosis. Eur J Gastroenterol Hepatol, 2016, 28(1): 57-63.
[20] Chalasani N, Wilson L, Kleiner DE, et al. Relationship of steatosis grade and zonal location to histological features of steatohepatitis in adult patients with non-alcoholic fatty liver disease. J Hepatol, 2008, 48(5): 829-834.
[21] Monzavi N, Zargar SJ, Gheibi N, et al. Angiopoietin-like protein 8 (betatrophin) may inhibit hepatocellular carcinoma through suppressing of the Wnt signaling pathway. Iran J Basic Med Sci, 2019, 22(10): 1166-1171.
[22] Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol, 2020, 73(1): 202-209.
[23] Kwok R, Choi KC, Wong GL, et al. Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study. Gut, 2016, 65(8): 1359-1368.
[24] Abu-Farha M, Abubaker J, Al-Khairi I, et al. Higher plasma betatrophin/ANGPTL8 level intype 2 diabetes subjects does not correlate with blood glucose or insulin resistance. Sci Rep, 2015, 5: 10949.
[25] Zhao Z, Deng X, Jia J, et al. Angiopoietin-like protein 8 (betatrophin) inhibits hepatic gluconeogenesis through PI3K/Akt signaling pathway in diabetic mice. Metabolism, 2022, 126: 154921.
[26] Rong Guo X, Li Wang X, Chen Y, et al. ANGPTL8/betatrophin alleviates insulin resistance via the Akt-GSK3β or Akt-FoxO1 pathway in HepG2 cells. Exp Cell Res, 2016, 345(2): 158-167.
[27] Espes D, Lau J, Carlsson PO. Increased circulating levels of betatrophin in individuals with long-standing type 1 diabetes. Diabetologia, 2014, 57(1): 50-53.
[28] Espes D, Martinell M, Carlsson PO. Increased circulating betatrophin concentrations in patients with type 2 diabetes. Int J Endocrinol, 2014, 2014: 323407.
[29] Gómez-Ambrosi J, Pascual E, Catalán V, et al. Circulating betatrophin concentrations are decreased in human obesity and type 2 diabetes. J Clin Endocrinol Metab, 2014, 99(10): 2004-2009.
[30] Gusarova V, Alexa CA, Na E, et al. ANGPTL8/betatrophin does not control pancreatic beta cell expansion. Cell, 2014, 159(3): 691-696.
[31] Cox AR, Lam CJ, Bonnyman CW, et al. Angiopoietin-like protein 8 (ANGPTL8)/betatrophin overexpression does not increase beta cell proliferation in mice. Diabetologia, 2015, 58(7): 1523-1531.
[32] Fenzl A, Itariu BK, Kosi L, et al. Circulating betatrophin correlates with atherogenic lipid profiles but not with glucose and insulin levels in insulin-resistant individuals. Diabetologia, 2014, 57(6): 1204-1208.
[33] Musso G, Gambino R, Cassader M. Cholesterol metabolism and the pathogenesis of non-alcoholic steatohepatitis. Prog Lipid Res, 2013, 52(1): 175-191.
[34] Lee YH, Lee SG, Lee CJ, et al. Association between betatrophin/ANGPTL8 and non-alcoholic fatty liver disease: animal and human studies. Sci Rep, 2016, 6: 24013.
[35] Kovrov O, Kristensen KK, Larsson E, et al. On the mechanism of angiopoietin-like protein 8 for control of lipoprotein lipase activity. J Lipid Res, 2019, 60(4): 783-793.

Perspective of betatrophin in the development of nonalcoholic fatty liver diseases

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Hou Yilin, Cao Fenghua, Ji Xiaoyan, et al. Changes of intestinal flora as well as serum interliukin-17 and interferon-γ levels in patients with nonalcoholic fatty liver diseases [J]. Journal of Practical Hepatology, 2023, 26(6): 819-822.
[2]	Gu Qi, Rui Fajuan, Ni Qianqian, et al. Chronic disease management in patients with nonalcoholic fatty liver diseases [J]. Journal of Practical Hepatology, 2023, 26(4): 457-459.
[3]	He Fangping. Practice of chronic disease management: What we should do in patients with non-alcoholic fatty liver diseases [J]. Journal of Practical Hepatology, 2023, 26(4): 460-462.
[4]	Yin Huifen, Yu Hongyan, Liu Zhiping. Changes of serum leptin, retinol-binding protein-4 and cholinesterase levels in patients with NAFLD and T2DM [J]. Journal of Practical Hepatology, 2023, 26(4): 500-503.
[5]	Fang Shanshan, Du Mingqiao, Wang Yue. Will the hypopituitarism lead to the occurrence of nonalcoholic fatty liver diseases? An preliminary study [J]. Journal of Practical Hepatology, 2023, 26(4): 504-507.
[6]	Qiu Liying, Wang Yingchun. Nonalcoholic fatty liver diseases and the intestinal microecology: Current state of the art, controversies, and perspectives [J]. Journal of Practical Hepatology, 2023, 26(3): 308-312.
[7]	Zhan Qirui, Duan Taimei, Yan Jie. Changes of serum amyloid A, plasma heme oxygenase-1 and bone morphogenetic protein 9 levels in patients with nonalcoholic fatty liver diseases [J]. Journal of Practical Hepatology, 2023, 26(3): 348-351.
[8]	Su Peihua, Song Meifang, Zhao Caiyan. Is the incidence of hepatocellular carcinoma increased in patients with chronic hepatitis B and nonalcoholic fatty liver diseases? [J]. Journal of Practical Hepatology, 2023, 26(3): 445-448.
[9]	Wei Li, Liu Bo, Zhao Nan, et al.. Would the coincidence of nonalcoholic fatty liver diseases impact the antiviral response to enticavir therapy in patients with chronic hepatitis B? [J]. Journal of Practical Hepatology, 2023, 26(2): 181-184.
[10]	Liu Gang, Zhang Hao, Hu Jun. Changes of serum miR-183-5p and miR-96-5p levels in patients with nonalcoholic fatty liver diseases [J]. Journal of Practical Hepatology, 2023, 26(2): 197-201.
[11]	Chen Fenglian, Zhu Qinglan, Zhu Lingli, et al. Different activation of peripheral blood invariant natural killer T cells and CD4⁺/CD8⁺T cells in patients with nonalcoholic fatty liver diseases [J]. Journal of Practical Hepatology, 2023, 26(1): 31-34.
[12]	Li Xiangyang, Ding Guangwei, Jin Ming. Efficacy of entecavir in treatment of patients with chronic hepatitis B and non-alcoholic fatty liver diseases [J]. Journal of Practical Hepatology, 2022, 25(6): 776-779.
[13]	Sun Ling, Hang Wei, Deng Guozhong. Short-term observation of metformin and pioglitazone combination in treatment of patients with non-alcoholic fatty liver diseases and diabetes mellitus type 2 [J]. Journal of Practical Hepatology, 2022, 25(6): 804-807.
[14]	Wang Xiaohua, Zeng Yalin, Guo Cuirong. Impact of impaired fasting glucose and insulin resistance on liver fibrosis in patients with nonalcoholic fatty liver diseases [J]. Journal of Practical Hepatology, 2022, 25(6): 812-815.
[15]	Liu Yantong, Yao Yang, Lu Bo. Short-term efficacy of Heye Tiaozhi Shugan Decoction in dealing with patients with nonalcoholic fatty liver diseases [J]. Journal of Practical Hepatology, 2022, 25(5): 657-660.